Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.

ABSTRACT:

Importance

Ibrutinib, a Bruton tyrosine kinase inhibitor, is a new targeted agent approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia. Ibrutinib is overall well tolerated but long-term treatment is required until disease progression or intolerable toxic effects occur. Little is known regarding its cutaneous adverse effects.

Objective

To describe the hair and nail manifestations associated with the long-term use of ibrutinib for the treatment of CLL.

Design, setting, and participants

Prospective study of 66 patients with CLL enrolled in a single-arm phase 2 clinical trial of ibrutinib for CLL between March 2014 and October 2015 at the National Institutes of Heal

SUBMITTER: Bitar C 

PROVIDER: S-EPMC6415534 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature